Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Core Insights - Biogen Inc. is set to present late-breaking data on litifilimab's efficacy in treating cutaneous lupus erythematosus (CLE) at the 2026 American Academy of Dermatology Annual Meeting, highlighting its potential as a first-in-class monoclonal antibody targeting BDCA2 [1][2] Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on innovative science to develop new medicines and create value for shareholders and communities [10] Product Development - Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody targeting BDCA2, currently under investigation for the treatment of systemic lupus erythematosus (SLE) and CLE [5][6] - The AMETHYST study is a two-part, Phase 2/3 multicenter, double-blind, placebo-controlled trial assessing the efficacy and safety of litifilimab in patients with active subacute and chronic CLE who are refractory or intolerant to antimalarial therapy [4][6] Regulatory Status - The U.S. FDA has granted litifilimab Breakthrough Therapy Designation for CLE, supported by results from the Phase 2 AMETHYST study and the Phase 2 LILAC study [2][6] Clinical Insights - The upcoming presentation will include 24-week results from the Phase 2 study, showcasing the safety and efficacy of litifilimab in treating CLE [3][6] - CLE is a serious autoimmune disease that can lead to significant quality of life impacts, with no approved targeted therapies available since the 1950s [9]